Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Jared KellyCEO | Oncolytics BiotechONCY | Open-market buy | 03/12 | 03/13 | 5,050 sh | $0.96 | $4,848 | +4.6% |
James T. ParsonsDirector | Oncolytics BiotechONCY | Open-market buy | 03/11 | 03/13 | 10,000 sh | $1.03 | $10,300 | +31.4% |
Patricia S. AndrewsDirector | Oncolytics BiotechONCY | Open-market buy | 02/12 | 02/13 | 35,400 sh | $0.86 | $30,444 | +82.8% |
Wayne PisanoDirector | Oncolytics BiotechONCY | Open-market buy | 02/12 | 02/13 | 30,000 sh | $0.84 | $25,200 | +6.5% |
Oncolytics BiotechONCY | Open-market buy | 02/11–02/12 | 02/13 | 100,000 sh2 trades | $0.84avg. | $83,800 | +21.4% | |
Thomas Charles HeinemanChief Medical Officer | Oncolytics BiotechONCY | Open-market buy | 02/12 | 02/13 | 12,132 sh | $0.83 | $10,069.56 | +4.5% |
Deborah Margaret BrownDirector | Oncolytics BiotechONCY | Open-market buy | 02/12 | 02/13 | 25,000 sh | $0.85 | $21,250 | +29.5% |
Oncolytics BiotechONCY | Open-market buy | 02/11–02/12 | 02/13 | 35,100 sh2 trades | $0.84avg. | $29,484 | +47.5% | |
Kirk LookCFO | Oncolytics BiotechONCY | Open-market buy | 02/12 | 02/13 | 12,000 sh | $0.84 | $10,080 | +4.4% |
Allison HagermanVP, Product Development | Oncolytics BiotechONCY | Open-market buy | 02/12 | 02/13 | 10,000 sh | $0.83 | $8,300 | +9.5% |
Andrew AromandoChief Business Officer | Oncolytics BiotechONCY | Open-market buy | 02/11 | 02/13 | 29,600 sh | $0.86 | $25,456 | +116.1% |
Bernd R. SeizingerDirector | Oncolytics BiotechONCY | Open-market buy | 01/16 | 01/20 | 100,000 sh | $1.04 | $104,000 | +27.2% |